Pyxis Oncology, Inc. (PYXS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Pyxis Oncology, Inc. reported revenue of $13.86M, down 14.2% from the prior year. The company ran a net loss, with a net margin of -574.5%. It held $91.52M in total assets against $38.11M in total liabilities.
Key ratios (FY2025)
-609.2%
Operating margin
-574.5%
Net margin
-149.1%
Return on equity
-14.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $13.86M | $16.15M | — | — | — | — | — |
| Cost of Revenue | $2.39M | $475.0K | — | — | — | — | — |
| Operating Income | -$84.42M | -$89.46M | -$82.20M | -$123.48M | -$69.72M | -$12.89M | — |
| Net Income | -$79.62M | -$77.33M | -$73.79M | -$120.72M | -$75.97M | -$12.83M | — |
| EPS (Diluted) | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-8.95 | — | — |
| Total Assets | $91.52M | $157.18M | $173.73M | $211.38M | $280.02M | $10.15M | — |
| Total Liabilities | $38.11M | $36.43M | $48.02M | $50.55M | $18.71M | $3.85M | — |
| Shareholders' Equity | $53.41M | $120.75M | $125.70M | $160.82M | $261.31M | -$15.64M | -$2.87M |
| Cash & Equivalents | $15.42M | $19.47M | $9.66M | $179.29M | $274.74M | $8.08M | — |
| Operating Cash Flow | -$63.50M | -$57.67M | -$70.71M | -$89.33M | -$35.33M | -$10.08M | — |
| Capital Expenditures | $9.0K | $237.0K | $6.73M | $6.40M | $540.0K | $1.48M | — |
| Shares Outstanding | 62.69M | 59.97M | 44.75M | 34.96M | 32.22M | 1.29M | — |